Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye

PURPOSE: To evaluate the safety and efficacy of ophthalmic MIM-D3, a tyrosine kinase TrkA receptor agonist, in patients with dry eye. DESIGN: A prospective, two-center, randomized, double-masked, placebo-controlled Phase 2 study. METHODS: A total of 150 dry eye patients were randomized 1:1:1 to stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Meerovitch, Karen, Torkildsen, Gail, Lonsdale, John, Goldfarb, Heidi, Lama, Teresa, Cumberlidge, Garth, Ousler, George W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699314/
https://www.ncbi.nlm.nih.gov/pubmed/23836957
http://dx.doi.org/10.2147/OPTH.S44688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699314/
https://www.ncbi.nlm.nih.gov/pubmed/23836957
http://dx.doi.org/10.2147/OPTH.S44688

Ejemplares similares